Clinical update

New treatment possibility for some cancer patients

Larotrectinib is approved by NICE as an option for NTRK fusion-positive solid tumours
Picture shows woman cancer patient lying in a hospital bed.

Larotrectinib is approved by NICE as an option for NTRK fusion-positive solid tumours

Essential facts

Larotrectinib is one of a new breed of cancer drugs designed to target specific changes in the DNA of cancer cells, rather than where the disease is growing in the body. This means patients, including children, with various cancer types may benefit from its use.

It is particularly useful for those patients at an advanced stage of cancer, when other options are limited or have been exhausted. The treatment aims to shrink tumours, potentially enough to make surgery a possibility for patients whose cancer could not otherwise be treated in this way.

What’s new?

After funding was initially rejected in January this year, larotrectinib was approved for NHS use in England in April, following successful negotiations between NHS England, the National Institute

...

Want to read more?

Unlock full access to RCNi Plus today

Save over 50% on your first three months:

  • Customisable clinical dashboard featuring 200+ topics
  • Unlimited online access to all 10 RCNi Journals including Cancer Nursing Practice
  • RCNi Learning featuring 180+ RCN accredited learning modules
  • NMC-compliant RCNi Portfolio to build evidence for revalidation
  • Personalised newsletters tailored to your interests

This article is not available as part of an institutional subscription. Why is this?

Jobs